Plus, there are other GLP-1 agonists in the market, like exenatide, sold under the brand name Byetta and Bydureon, among others, which was the first of its kind to get approval as an anti-diabetic from the FDA, in 2005
: USB
The key is ensuring competence: Take CME courses in obesity medicine (60+ hours for ABOM certification) Understand when to refer (e.g., suspected Cushings syndrome, complex endocrine issues) Collaborate with primary care when appropriate Document that the intervention is part of comprehensive patient care If youre treating a patients depression and their olanzapine-induced 40-pound weight gain is worsening that depression, prescribing a GLP-1 isnt scope creep its integrated psychiatry
It was one big nightmare from there." As in the United States, Ozempic is approved in Australia for people with type 2 diabetes not weight-loss as the Australian government's Department of Health and Aged Care noted in September when addressing its shortage
This lets users test a change for two weeks and see clear trends rather than random data
10.1002/mrd.1080420409 68 DemedtsM.BehrJ.BuhlR.CostabelU.DekhuijzenR.JansenH
